3 AI Healthcare Stocks Retail Investors Are Watching For Real World Adoption

Artificial intelligence in healthcare is moving from buzzword to practical toolkit just as global growth, easing inflation pressures, and more flexible central bank policies create a friendlier backdrop for risk assets. AI is helping doctors interpret scans, tailor treatments, and run hospitals more efficiently, while also supporting telemedicine and faster drug research. The Transformative AI Healthcare Stocks screener focuses on companies plugged into these trends and benefiting from real-world adoption of AI tools. This article highlights three notable stocks from that screener to illustrate how this theme might fit into a diversified portfolio.

Eastwood Bio-Medical Canada (TSXV:EBM)

Overview: Eastwood Bio-Medical Canada develops and markets Eleotin branded natural health products aimed at metabolic disorders such as blood glucose issues, hypertension, and obesity, along with a wider range of supplements for cardiovascular, bone, digestive, and mental health. The company is also working with BioNexus to apply artificial intelligence to large herbal prescription datasets in search of new natural drug and functional food candidates.

Operations: Eastwood Bio-Medical Canada generates about CA$0.79m in revenue from distributing Eleotin and related products, with most sales coming from Asia and smaller contributions from Canada and the U.S.

Market Cap: CA$81.97m

Eastwood Bio-Medical Canada sits at the crossroads of traditional herbal remedies and AI assisted product discovery. This gives the small Eleotin franchise a potentially differentiated angle in the crowded natural health space. Revenue of roughly CA$0.30m in the first half of 2026 and a continuing loss highlight the early stage and high risk nature of the business, especially given negative equity and heavy reliance on external borrowing. At the same time, losses have been reduced over the past five years and the joint AI research platform with BioNexus on around 250,000 blood glucose related prescriptions adds a data driven dimension that many supplement companies lack. Investors watching this stock may want to understand how those risks compare with the potential benefits if the AI project starts to deliver new products.

Eastwood Bio-Medical Canada is trying to turn a modest Eleotin footprint and AI assisted herbal research into something bigger. Yet the real story may sit in how its risks stack up against that promise, which is exactly what you will find in the 1 key reward and 3 important warning signs (2 are major!)

Profound Medical (TSX:PRN)

Overview: Profound Medical develops AI powered, MRI guided systems that let doctors ablate diseased tissue inside the body without incisions, focusing today on prostate cancer and other benign tumors. Its core TULSA-PRO and Sonalleve platforms aim to treat conditions like prostate disease, uterine fibroids and painful bone metastases while limiting side effects and preserving quality of life.

Operations: Profound Medical generates about $18.81m in annual revenue from its Medical Technology business, with around $12.32m from the U.S., $5.80m from Canada, and a smaller $0.70m from Germany.

Market Cap: CA$427.33m

Profound Medical sits in a high interest corner of healthcare where AI, imaging and minimally invasive treatment meet. This is one reason the stock often attracts attention from growth focused investors. Earnings and revenue are both forecast to grow sharply and recent TULSA-PRO data from the CAPTAIN trial in July 2026 point to potential quality of life benefits over robotic prostatectomy, including preservation of penile length and efforts to reduce incontinence and erectile dysfunction. At the same time, the company is still loss making, return on equity is deeply negative and funding relies heavily on external borrowing, while the P/S multiple is well above industry averages. Combined with past dilution and rich CEO pay, the overall risk reward trade off may warrant closer inspection.

Profound Medical’s AI surgery story is gathering pace; however, the real puzzle is how that growth profile stacks up against dilution, debt and valuation pressure. Get the full picture in the analyst forecasts for Profound Medical

Perimeter Medical Imaging AI (TSXV:PINK)

Overview: Perimeter Medical Imaging AI develops medical imaging systems that give surgeons real time, cross sectional views of excised tissue in the operating room, with AI support to help assess whether cancer margins have been fully removed, particularly in breast conservation surgery. It also supplies a proprietary image library and consumable specimen containers to hospitals and cancer centers.

Operations: Perimeter Medical Imaging AI generates about $2.14m in revenue from Medical Imaging Systems, all currently from Canada.

Market Cap: CA$46.03m

Perimeter Medical Imaging AI sits at the intersection of AI and cancer surgery, with its Claire OCT system and ImgAssist software aiming to help surgeons reduce repeat operations by giving clearer margin information in the operating room. Revenue is still modest and the company remains loss making, with deeply negative return on equity and a funding mix that leans heavily on higher risk external borrowing and recent convertible debentures. At the same time, forecast revenue growth of around 48% a year, fresh funding support from INOVAIT and Mitacs, and new coverage from Brookline indicate rising interest in the story. The key consideration for investors is how that growth potential balances against ongoing losses and shareholder dilution, along with the potential impact if AI performance in future trials influences adoption.

Perimeter Medical Imaging AI sits at the intersection of AI assisted cancer surgery, fresh funding and early revenue, yet the real story is how that balance of promise and dilution risk shows up in the analysis report for Perimeter Medical Imaging AI

The three AI healthcare stocks in this article are just the starting point, as the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaced four more companies with equally compelling AI in healthcare narratives that you have not seen yet. Use Simply Wall St to identify and analyze the specific catalysts, data trends and risk factors that matter most to you so you can focus on the highest conviction opportunities in this theme.

Take Control of Your Investment Journey

If Profound Medical or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

Fresh stock ideas can move from under the radar to full breakout quickly. Use these curated picks before the early momentum is caught by the crowd. Act now.

• Spot income workhorses that aim to keep paying even when headlines turn rough by using the curated 6 dividend fortresses and decide if any fit your income goals.
• Track potential compounding machines powered by structural demand shifts through the carefully filtered 36 power grid technology and infrastructure stocks so you stay close to companies supporting tomorrow’s energy backbone.
• Hunt for rare growth stories tied to security, payments and decentralized infrastructure using the focused 20 cryptocurrency and blockchain stocks and review which business models still look under the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com